Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of
Express News | Ventyx Biosciences Shares Are Trading Higher. The Company Appointed Matthew Moore as COO
Ventyx Biosciences Gets New Operations Chief
Express News | Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
Press Release: Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), ("Ventyx"), a clinical-stage
Stifel Nicolaus Keeps Their Hold Rating on Ventyx Biosciences (VTYX)
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)
Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Ventyx Biosciences: A Prudent Hold Amidst Promising Drug Potential and Market Uncertainties
Buy Rating for Ventyx Biosciences Based on Clinical and Financial Strengths
Express News | Ventyx Biosciences Inc - Qtrly Net Loss $38.6 Mln
Ventyx Biosciences | 10-Q: Quarterly report
Express News | Ventyx Biosciences: Cash, Cash Equivalents & Marketable Securities as of March 31, 2024 Expected to Fund Planned Operations Into at Least H2of 2026
Express News | Ventyx Biosciences Q1 2024 GAAP EPS $(0.62) Beats $(0.67) Estimate
Ventyx Biosciences 1Q Loss $38.6M >VTYX
Ventyx Biosciences 1Q Loss $38.6M >VTYX
Express News | Ventyx Biosciences Q1 Operating Expenses USD 41.768 Million
Express News | Ventyx Biosciences Q1 Net Income USD -38.572 Million Vs. Ibes Estimate USD -41.2 Million
Express News | Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress